Maze Therapeutics (MAZE) Earnings Date & Reports

Maze Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2025, aligning with its standard calendar fiscal year. No license revenue was recorded in Q4 2025 ($0 million), matching prior quarter but down from full-year 2024's $167.5 million upfront from Shionogi for MZE001. Research and development (R&D) expenses increased 24% to $27.6 million in Q4 from $22.2 million year-over-year, reflecting higher clinical trial and manufacturing costs for MZE829 (APOL1 inhibitor) and MZE782, plus personnel expenses. General and administrative (G&A) expenses rose to $10.5 million from $7.5 million.

Net loss widened to $34.6 million ($0.65 per share, basic and diluted) from $29.6 million in Q4 2024, beating Wall Street's ($0.73) EPS consensus. Full-year net loss was $131.1 million ($3.05 per share), versus 2024 net income of $52.2 million driven by the licensing deal.

Key metrics included positive HORIZON Phase 2 topline: MZE829 achieved 35.6% mean proteinuria reduction (uACR) at week 12 in broad AMKD patients, with 50% hitting >30% drop; 61.8% in severe FSGS subset. No serious adverse events. Maze plans pivotal trials while continuing enrollment. Cash grew to $360 million, up from $196.8 million, supporting runway into 2028. These exceeded financial expectations but clinical data mixed against lofty pre-report hopes.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.

Market Reaction and Investor Sentiment

MAZE shares plunged ~35% on March 25, 2026, closing near $31 from prior $49, on heavy volume of over 3 million shares, despite EPS beat and positive HORIZON data. Investors appeared disappointed by uACR reductions falling short of peak expectations for the elevated valuation, triggering profit-taking amid clinical limitations like small cohorts. Subsequent trading saw volatility, with partial recovery but ongoing pressure, reflecting biotech sensitivity to milestone nuances over financials.

Forward Outlook and Key Factors to Monitor

Maze's $360 million cash pile funds operations into 2028, providing ample runway for pipeline execution without near-term dilution risks. Investors should track advancement of MZE829 into pivotal trials for AMKD, including full HORIZON data and enrollment progress.

Upcoming catalysts include Phase 2 initiations for MZE782: mid-2026 for phenylketonuria (PKU) plasma Phe reduction, second half for chronic kidney disease (CKD) proteinuria. MZE001 hit a $20 million milestone from Shionogi for ESPRIT Phase 2 dosing in Pompe disease, with potential for $255 million more in clinical/regulatory milestones plus royalties.

Monitor R&D burn amid rising clinical costs, margin on partnerships, and Board addition of Neil Kumar for strategic input. Broader kidney biotech dynamics, like APOL1 competition, will shape sentiment. Next earnings, estimated Q1 2026 in May, will update these milestones.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations